2013-01-22 07:48:01 -
Novartis International AG /
Novartis receives EU approval for Bexsero®, first vaccine to prevent the leading
cause of life-threatening meningitis across Europe
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Bexsero is indicated to help protect all age groups against meningococcal
serogroup B (MenB) disease, including infants who are the most vulnerable[1]
* MenB disease is associated with a high human toll for families and
communities, as it can be fatal or may cause serious, life-long disabilities
in survivors[2],[3]
* Novartis is working with health authorities to provide access to Bexsero as
soon as possible
Basel, January 22, 2013 - Novartis announced today that the European Commission
has approved Bexsero(®) (Meningococcal Group B Vaccine [rDNA, component,
adsorbed]) for use in individuals from 2 months of age and older. Novartis is
committed to making Bexsero available as soon as possible.
"This meningitis B vaccine is the most important medical breakthrough in the 30
years since I lost my son to the disease," said Meningitis UK Founder Steve
Dayman MBE. "It could save thousands of lives and prevent other parents
suffering the same tragedy. The vaccine must be made widely available through
the immunisation schedule as soon as possible - any delay could mean lives
lost."
MenB disease is a bacterial infection and is the leading cause of meningitis
across Europe[4], particularly in infants[1]. Although rare, one reason this
disease is so feared is that it affects healthy people rapidly and without
warning[2],[3]. Symptoms can often resemble the flu, making this disease easily
misdiagnosed in its early stages[5]. In many cases, doctors simply cannot treat
infected patients soon enough to avoid serious outcomes. About one in ten of
those who contract the disease will die despite appropriate treatment[3]. Up to
one in five survivors may suffer from devastating, life-long disabilities such
as brain damage, hearing impairment or limb loss[3]. Prevention through
vaccination is therefore the best defense against this aggressive disease.
"Each year, thousands of parents see their children die or left with severe
disabilities as a result of this devastating disease. Through the combined
efforts of many people over two decades, we are closer than ever to seeing an
end to this suffering," said Andrin Oswald, Division Head, Novartis Vaccines and
Diagnostics. "Our vision is a world without meningitis, and our priority is to
work with decision makers across Europe to ensure there is broad and timely
access to vaccination."
Following today's approval, EU member states will evaluate Bexsero for potential
inclusion into national immunization programs and, where relevant, reimbursement
schemes. Novartis is already engaging with governments interested in the early
adoption of the vaccine.
Bexsero is the result of more than 20 years of pioneering vaccine research[6],
and its tolerability profile and immunogenicity have been established through a
comprehensive clinical program involving infants, children, adolescents and
adults[7],[8],[9],[10],[11],[12]. Starting at two months of age, Bexsero offers
several immunization schedule options that could fit with routine vaccination
visits.
The approval of Bexsero underscores the unique leadership position of Novartis
in the global fight against devastating meningococcal disease. Together, Bexsero
and Menveo(®) help to protect against all five main serogroups of meningococcal
bacteria (A, C, W-135, Y and now B) that cause the majority of cases around the
world[13].
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "as soon as possible," "committed,"
"could," "vision,"
"priority," "will," "potential," or similar expressions, or by
express or
implied discussions regarding the potential timing of the availability of
Bexsero to the public, or regarding potential future revenues from Bexsero. You
should not place undue reliance on these statements. Such forward-looking
statements reflect the current views of management regarding future events, and
involve known and unknown risks, uncertainties and other factors that may cause
actual results with Bexsero to be materially different from any future results,
performance or achievements expressed or implied by such statements. There can
be no guarantee that Bexsero will be available to the public in any particular
country at any particular time. Nor can there be any guarantee that Bexsero will
achieve any particular levels of revenue in the future. In particular,
management's expectations regarding Bexsero could be affected by, among other
things, unexpected regulatory actions or delays or government regulation
generally, including uncertainties as to whether Bexsero will be included in
particular countries' national immunization programs; unexpected clinical trial
results, including unexpected new clinical data and unexpected additional
analysis of existing clinical data; government, industry and general public
pricing pressures; unexpected manufacturing issues; the company's ability to
obtain or maintain patent or other proprietary intellectual property protection;
the impact that the foregoing factors could have on the values attributed to the
Novartis Group's assets and liabilities as recorded in the Group's consolidated
balance sheet, and other risks and factors referred to in Novartis AG's current
Form 20-F on file with the US Securities and Exchange Commission. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those
anticipated, believed, estimated or expected. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2011, the Group's
continuing operations achieved net sales of USD 58.6 billion, while
approximately USD 9.6 billion (USD 9.2 billion excluding impairment and
amortization charges) was invested in R&D throughout the Group. Novartis Group
companies employ approximately 127,000 full-time-equivalent associates and
operate in more than 140 countries around the world. For more information,
please visit
www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at
twitter.com/novartis.
References
[1] Rosenstein NE, et al. Meningococcal disease. N Engl J Med 2001;344:1378-88.
[2] Thompson MJ, et al. Clinical recognition of meningococcal disease in
children and adolescents. Lancet 2006;367:397-403.
[3] World Health Organization. Meningococcal meningitis. Fact sheet #141.
November 2012 update. Available at:
www.who.int/mediacentre/factsheets/fs141/en/. Last accessed 15 Jan 2013.
[4] World Health Organization. Meningococcal, staphylococcal and streptococcal
infections. Available at:
www.who.int/vaccine_research/documents/Meningo20091103.pdf. Last accessed
15 Jan 2013.
[5] Mayo Foundation for Medical Education and Research. Meningitis. April 2011.
Available at:
www.mayoclinic.com/health/meningitis/DS00118/DSECTION=symptoms. Last
accessed 15 Jan 2013.
[6] Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine
development. Vaccine 2001;19:2688-91.
[7] Santolaya ME, et al. Immunogenicity and tolerability of a multicomponent
meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile.
Lancet 2012;379:617-24.
[8] Gossger N, et al. Immunogenicity and tolerability of recombinant
meningococcal serogroup B vaccine administered with or without routine infant
vaccinations according to different immunization schedules: A randomized
controlled trial. JAMA 2012;307:573-82.
[9] Vesikari T, et al. Immunogenicity and safety of an investigational
multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB)
administered concomitantly with routine infant and child vaccinations: results
of two randomised trials. Lancet 2013 Jan 14. [Epub ahead of print].
[10] Findlow J, et al. Multicenter, open-label, randomized phase II controlled
trial of an investigational recombinant meningococcal serogroup B vaccine with
and without outer membrane vesicles, administered in infancy. Clin Infect Dis
2010;51:1127-37.
[11] Snape MD, et al. Immunogenicity of two investigational serogroup B
meningococcal vaccines in the first year of life: a randomized comparative
trial. Pediatr Infect Dis J 2010;29:e71-9.
[12] Prymula R, et al. Catch-up vaccination of healthy toddlers with an
investigational multicomponent meningococcal serogroup B vaccine (4CMenB) -
exploration of a two-dose schedule. Presented at 29th ESPID Meeting, 7-11 June
2011; The Hague, The Netherlands.
[13] World Health Organization. Meningococcal position paper. Weekly
epidemiological record No. 44, 2002, 77, 329-40. Available at:
www.who.int/immunization/wer7740meningococcal_Oct02_position_pap ...
Last accessed 15 Jan 2013.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Liz Power
Novartis Global Media Relations Novartis Division Communications
+41 61 324 7999 (direct) +1 617 871 7985 (direct)
+41 79 593 4202 (mobile) +1 617 583 3015 (mobile)
eric.althoff@novartis.com elizabeth.power@novartis.com
e-mail:
media.relations@novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp@thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944 North America:
Samir Shah +41 61 324 7944 Helen Boudreau +1 212 830 2404
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 83 01
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail:
investor.relations@novartis.com e-mail:
investor.relations@novartis.com
Media release (PDF):
hugin.info/134323/R/1672036/543712.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1672036]
